The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PLX | +4.68% | -53.51% | -14.19% | -99% |
| S&P | +13% | +86.41% | +13.26% | +378% |
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.
Investors did not like the company's latest regulatory update.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.85M | -0.6% |
| Gross Profit | $9.53M | -0.6% |
| Gross Margin | 53.37% | 0.0% |
| Market Cap | $177.01M | 136.0% |
| Market Cap / Employee | $0.83M | 0.0% |
| Employees | 213 | 2.4% |
| Net Income | $2.36M | -27.2% |
| EBITDA | $2.50M | -42.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $13.65M | -50.2% |
| Accounts Receivable | $14.43M | 557.2% |
| Inventory | 21.3 | 23.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.78M | 62.4% |
| Short Term Debt | $1.40M | -7.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.50% | 20.4% |
| Return On Invested Capital | -23.41% | -23.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.23M | -205.3% |
| Operating Free Cash Flow | -$3.73M | -190.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 71.48 | 60.95 | 20.00 | 31.94 | -42.96% |
| Price to Book | 4.27 | 4.49 | 2.56 | 3.55 | 35.60% |
| Price to Sales | 2.67 | 3.28 | 1.94 | 2.90 | 59.93% |
| Price to Tangible Book Value | 4.27 | 4.49 | 2.56 | 3.55 | 35.60% |
| Price to Free Cash Flow TTM | 21.06 | 11.55 | 19.29 | - | |
| Enterprise Value to EBITDA | 15.02 | -43.86 | 60.20 | 63.21 | 346.80% |
| Free Cash Flow Yield | 4.7% | 8.7% | 5.2% | - | |
| Return on Equity | 7.6% | 10.4% | 16.0% | 12.6% | -146.51% |
| Total Debt | $5.53M | $5.24M | $5.35M | $8.18M | 43.86% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
